Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
New Delhi metallo-β-lactamase (NDM-1) is a serious threat to the existing antibiotic armory, and a potent weapon for bacteria to aid in in their ‘battle’. It has the ability to inactivate all β-lactams, except aztreonam. However, most of the NDM-1-producers also produce aztreonam hydrolysing-β-lactamases, thereby making these pathogens absolutely resistant to all β-lactams. This minireview incorporates a concise update on global epidemiology (2009- 2012) of NDM-1. However, the crux of the discussion is to focus on paucity of clinically useful therapeutic options, and suggest a solution to the drug resistance threat imposed by NDM-1 bacterial enzyme.
Citation: Shakil S, Ahmad A, Tabrez S, Ashraf GM, Khan AAP (2013) A Regionspecific Treatment Strategy To Address The Problem Of Drug Resistance By NDM-1-producing Pathogens. Enz Eng 2:107.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi